JP2024512121A - アルカフタジンを含む鼻用組成物 - Google Patents

アルカフタジンを含む鼻用組成物 Download PDF

Info

Publication number
JP2024512121A
JP2024512121A JP2023560146A JP2023560146A JP2024512121A JP 2024512121 A JP2024512121 A JP 2024512121A JP 2023560146 A JP2023560146 A JP 2023560146A JP 2023560146 A JP2023560146 A JP 2023560146A JP 2024512121 A JP2024512121 A JP 2024512121A
Authority
JP
Japan
Prior art keywords
composition
nasal
alcaftadine
composition according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512121A5 (https=
Inventor
アキレシュ・シャルマ
ババサヘブ・アワレ
ヴィラジ・シャー
アモル・アイワレ
Original Assignee
アルケム・ラボラトリーズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルケム・ラボラトリーズ・リミテッド filed Critical アルケム・ラボラトリーズ・リミテッド
Publication of JP2024512121A publication Critical patent/JP2024512121A/ja
Publication of JP2024512121A5 publication Critical patent/JP2024512121A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023560146A 2021-04-01 2021-06-14 アルカフタジンを含む鼻用組成物 Pending JP2024512121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (2)

Publication Number Publication Date
JP2024512121A true JP2024512121A (ja) 2024-03-18
JP2024512121A5 JP2024512121A5 (https=) 2024-06-18

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560146A Pending JP2024512121A (ja) 2021-04-01 2021-06-14 アルカフタジンを含む鼻用組成物

Country Status (12)

Country Link
US (6) US20240173331A1 (https=)
EP (1) EP4312973A1 (https=)
JP (1) JP2024512121A (https=)
KR (1) KR20230163413A (https=)
CN (1) CN117120029A (https=)
AU (1) AU2021437358A1 (https=)
BR (1) BR112023019795A2 (https=)
CA (1) CA3213156A1 (https=)
CL (1) CL2023002871A1 (https=)
MX (1) MX2023011546A (https=)
WO (1) WO2022208146A1 (https=)
ZA (1) ZA202308388B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533333A (ja) * 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PL1919450T3 (pl) 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
WO2021255622A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533333A (ja) * 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT MEDICAL RESEARCH & OPINION, vol. 27, no. 3, JPN6025023742, 2011, pages 623 - 631, ISSN: 0005619866 *
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 27, no. 2, JPN6025023741, 2011, pages 187 - 195, ISSN: 0005760297 *

Also Published As

Publication number Publication date
US20250064825A1 (en) 2025-02-27
KR20230163413A (ko) 2023-11-30
MX2023011546A (es) 2023-10-06
US12274702B2 (en) 2025-04-15
US20240173331A1 (en) 2024-05-30
US20250064827A1 (en) 2025-02-27
BR112023019795A2 (pt) 2023-11-07
EP4312973A1 (en) 2024-02-07
US20260007682A1 (en) 2026-01-08
US20250064826A1 (en) 2025-02-27
WO2022208146A1 (en) 2022-10-06
CA3213156A1 (en) 2022-10-06
US20250064828A1 (en) 2025-02-27
AU2021437358A1 (en) 2023-09-14
ZA202308388B (en) 2025-11-26
CN117120029A (zh) 2023-11-24
CL2023002871A1 (es) 2024-01-26

Similar Documents

Publication Publication Date Title
US12274702B2 (en) Nasal compositions comprising alcaftadine
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
JP5683719B2 (ja) ベポタスチン組成物
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
US6740660B2 (en) Nasal delivery of apomorphine
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
KR20170130443A (ko) 엔도텔린 수용체 길항제의 국소 안용 제형
US20040101484A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
KR101099826B1 (ko) 항알러지성 약물을 활성성분으로 함유하는 비강투여용 액상제제
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
JPH11147825A (ja) 粘膜吸収性の向上方法及び粘膜外用剤
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
Bonnin et al. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel
TW202211919A (zh) 蕈毒鹼性促效劑眼用製劑及其用途
EA041383B1 (ru) Интраназальная композиция, включающая бетагистин
NZ616149B2 (en) Nasal Pharmaceutical Formulation Comprising Fluticasone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423